glp/gip/glucagon & cagrilintide 8mg/2mg Exciting News! 🗞️ Retatrutide is currently being tested as one of the first triple hormone receptor agonist to help patients who are currently struggling with what is already out in the market! The Road towards Triple Agonists:

That last clause is the one that distinguishes a prescription peptide from a supplement

Mikki can create a multi-modal approach that addresses your health goals from multiple angles

At CoreAge Rx, we serve as your comprehensive health and wellness partner for various conditions

Product Purity & Contamination Concerns The major BPC-157 contamination risk comes from purchasing tainted or mislabeled vials from the research use only market, especially when no valid COA is provided

On April 23, 2026 it came off the FDAs Category 2 do not compound list, and its one of seven peptides the FDAs Pharmacy Compounding Advisory Committee (PCAC) reviews on July 23-24, 2026 for 503A compounding eligibility